Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Anti-ccr7 mab for the prevention or treatment of graft-versus-host disease (GVHD)

A technology for implants, uses, and applications in the fields of biopharmaceuticals, medicine and pharmacy

Pending Publication Date: 2021-10-26
弹射器治疗有限公司 +1
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these documents reveal that targeting CCR7 can be effectively used to prevent or treat GVHD without the disadvantages of the side effects of the prior art methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Anti-ccr7 mab for the prevention or treatment of graft-versus-host disease (GVHD)
  • Use of Anti-ccr7 mab for the prevention or treatment of graft-versus-host disease (GVHD)
  • Use of Anti-ccr7 mab for the prevention or treatment of graft-versus-host disease (GVHD)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0053] The present invention is based on the discovery that the CCR7 receptor is highly expressed in some lymphocytes and antigen presenting cells (APC). In said cells, CCR7 plays a major role in entry into lymphoid tissues including lymph nodes (LN), which is the basis for the occurrence and evolution of GVHD. The present inventors surprisingly found that anti-CCR7 antibodies produced a significant therapeutic effect in a mouse model of GVHD. GVHD can be inhibited without significant side effects by administering anti-CCR7 antibodies to graft recipients. In vivo models show how antibodies targeting CCR7 can prevent disease and ameliorate GVHD once it occurs, making the CCR7 receptor an interesting target for mAb therapy in both acute and chronic GVHD. Monoclonal antibody (mAb) to CCR7, that is, an antibody that recognizes an epitope in the CCR7 receptor and preferably inhibits CCR7-dependent intracellular signaling, which can kill CCR7 in vivo + Donor and recipient immune c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel therapeutic agent in prevention and / or treatment of graft versus host disease (GVHD), preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. GVHD of the invention can be acute (aGVHD) and / or chronic (cGVHD), preferably acute. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro immune cells expressing CCR7 and are capable in vivo of selectively killing immune cells expressing a CCR7 receptor and of impairing / blocking migration and of activation of said immune cells, which are involved in the development and evolution of GVHD. The use of said antibodies for depleting, killing and impairing / blocking migration and activation of immune cells expressing CCR7 cells is disclosed, thus providing an alternative therapy for preventing and treating GVHD in both acute and chronic types.

Description

[0001] field of invention [0002] The present invention generally relates to the fields of medicine and pharmacy, and in particular to the field of biopharmaceuticals for organ, tissue or cell transplantation and implantation. More specifically, the present invention relates to anti-CCR7 receptor antibodies useful for the prevention and treatment of graft-versus-host disease. Background technique [0003] In recent years, hematopoietic stem cell transplantation (HSCT) has been widely used for the purpose of treating various blood system diseases, such as hematopoietic organ tumors, leukemia or dysplastic anemia. In addition, cell transplantation is also a useful treatment in the medical field. HSCTs are classified according to differences in stem cell source or donor selection. Common sources of stem cells include bone marrow harvested from the iliac crest (Aschan.J.Br Med Bull.2006; 77-78:23-36), granulocyte colony-stimulating factor (G-CSF), or peripheral blood stem cells...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P37/06A61K39/00
CPCA61K39/00A61P37/06A61K2039/505C07K16/2866C07K2317/734C07K2317/76C07K2317/92
Inventor C·奎斯塔马特奥斯C·穆尼奥斯卡列哈I·波特罗赛恩斯M·D·V·戈麦斯加西亚德索里亚M·L·托里维奥F·特罗恩费尔南德斯
Owner 弹射器治疗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com